Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections
Citations Over TimeTop 10% of 2003 papers
Abstract
Dalbavancin, a novel glycopeptide with a long elimination half-life ( approximately 9-12 days), was compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In a randomized, controlled, open-label, phase 2 proof-of-concept trial, adults received 1100 mg of dalbavancin (as a single intravenous infusion), 1000 mg of dalbavancin intravenously and then 500 mg intravenously 1 week later, or a prospectively defined standard-of-care regimen. A gram-positive pathogen was isolated from samples obtained from 41 (66%) of 62 patients at baseline; Staphylococcus aureus was the most prevalent species (83% of pathogens). Clinical success rates at a follow-up visit (test of cure) were 94.1% among patients treated with 2 doses of dalbavancin, 61.5% among patients treated with 1 dose of dalbavancin, and 76.2% among patients treated with a standard-of-care regimen. All treatment regimens were well tolerated; drug-related adverse reaction rates were similar across the 3 groups. These findings suggest that a regimen of 2 doses of dalbavancin administered 1 week apart is effective in the treatment of complicated, gram-positive bacterial SSTIs and warrants further study.
Related Papers
- → Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections(2017)15 cited
- → Stewarding the Costly Antibiotic: Considerations for Dalbavancin(2020)5 cited
- → Dalbavancin in the treatment of skin and soft tissue infections(2018)2 cited
- → EPH49 Nosocomial Infections With Methicillin-Resistant Staphylococcus Aureus (SARM) Potentially Avoided With the Use of Dalbavancin During Hospital Treatment of Acute Bacterial Skin and Skin Structure Infections in Spain(2022)
- → EE669 Use of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis(2022)